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Abstract Molecular shape, flexibility, and surface hydro-
philicity are thought to influence the ability of nanoparticles
to cross biological barriers during drug delivery. In this
study, coarse-grained (CG) molecular dynamics (MD)
simulations were used to study these properties of a
polymer-drug construct in potential clinical development:
poly(γ-glutamyl-glutamate)-paclitaxel-poly(ethylene gly-
col) nonpeptide RGD (PGG-PTX-PEG-npRGD), a linear
glutamyl-glutamate polymer with paclitaxel and poly(eth-
ylene glycol)-nonpeptide RGD side groups. It was hypoth-
esized that the PEG molecular weight (MW) (500 Da;
1,000 Da; and 2,000 Da) and nonpeptide RGD ligand
density (4, 8, 12, and 16 per molecule), respectively, may
have advantageous effects on the shape, flexibility, and
surface hydrophilicity of PGG-PTX-PEG-npRGD. Circular
dichroism spectroscopy was used to suggest initial struc-
tures for the all-atom (AA) models of PGG-PTX-PEG-
npRGD, which were further converted to CG models using
a commercially available mapping algorithm. Due to its
semi-flexibility, PGG-PTX-PEG-npRGD is not limited to
one specific conformation. Thus, CG MD simulations were
run until statistical equilibrium, at which PGG-PTX-PEG-
npRGD is represented as an ensemble of statistically similar
conformations. The size of a PGG-PTX-PEG-npRGD
molecule is not affected by the PEG MW or the nonpeptide
RGD density, but higher PEG MW results in increased
surface density of a PGG-PTX-PEG-npRGD molecule.
Most PGG-PTX-PEG-npRGD shapes are globular, al-
though filamentous shapes were also observed in the
PEG500 and PEG1000 molecules. PEG500 and PEG1000
molecules are more flexible than PEG2000 systems. A
higher presence of npRGD ligands results in decrease
surface hydrophilicity of PGG-PTX-PEG-npRGD. These
results indicate that the PGG-PTX-PEG1000-npRGD4 and
PGG-PTX-PEG1000-npRGD8 molecules are the most
efficacious candidates and are further recommended for
experimental preclinical studies.
Keywords Polymer.Paclitaxel.Poly(ethylene glycol).
Nonpeptide RGD.Active targeting.Coarse-grained
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Introduction
A continuing challenge in the development of anticancer
therapeutics is ensuring that adequate amounts of the drug
are delivered to tumors while simultaneously minimizing
toxic and adverse effects to healthy tissue [1, 2]. As
angiogenesis is crucial for tumor growth, the microvascular
endothelial cell and its receptors have become key target
modulators in cancer therapy [3]. The αVβ3 integrin and its
ligands, vitronectin and fibronectin, are known to promote
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DOI 10.1007/s00894-011-0989-4angiogenesis [4, 5], and tumor cells with non-activated αVβ3
integrins have been shown to exhibit decreased angiogenic
behavior [6]. As a result, antagonists of αVβ3 integrins have
emerged as a new class of anticancer therapeutics, primarily
the Arg-Gly-Asp (RGD) tripeptide and RGD peptidomimet-
ics, which bind to αVβ3 integrins with high affinity to prevent
binding of αVβ3 integrins to their natural receptors [7–9].
This study focuses on the preclinical development of a
nonpeptide RGD (npRGD)-based drug delivery system:
poly(γ-glutamyl-glutamate) paclitaxel tethered to npRGD
via poly(ethylene glycol) (PGG-PTX-PEG-npRGD) [10].
Paclitaxel (Taxol
®,C 47H51NO14) (PTX) is a hydrophobic
drug used to treat breast, ovarian, and lung cancers, and
poly(γ-glutamyl-glutamate) (PGG) is a hydrophilic polymer
conjugated to PTX to improve solubility [11, 12]. To
maximize access of npRGD to αVβ3 integrins, PEG is
positioned between glutamyl-glutamate and npRGD residues
to avoid steric interactions between PGG-PTX and npRGD
(see Fig. 1). Conjugation of PEG to therapeutic agents has
also been shown to result in improved in vivo stability,
protection from proteolytic digestion, increased biological
half-life, improved solubility, and decreased toxicity [13].
Preclinical development of anticancer therapeutics usu-
ally involves trial-and-error testing of candidate compounds
on in vitro and in vivo models. While these methods yield
useful results, they are time-consuming, inefficient, and
resource-intensive. Given to urgent clinical need for
successful therapies there is clear motivation to shorten
the course of preclinical development of therapeutic agents.
In this study, we performed molecular dynamics (MD)
simulations of PGG-PTX to predict their physicochemical
properties, such as shape, flexibility, and surface hydro-
Fig. 1 Chemical structures of
poly(γ-glutamyl-glutamate)
(GG), GG-paclitaxel (PTX), and
GG-poly(ethylene glycol)
(PEG)-npRGD [non-peptide
residues RGD (Arg-Gly-Asp)
peptidomimic]. GGNH3+ and
GG-PTX each has a charge of
−1; GG and GG-PEG-npRGD
each a charge of −2; and
GGCOO– a charge of −3. The
GG residue differs slightly
based on its position on the
polymer, e.g., its position at the
amino or carboxyl termini. For
the GG-PTX residue, paclitaxel
is conjugated to a carboxylate
group of glutamyl-glutamate via
an ester linkage. For the GG-
npRGD residue, the nonpeptide
RGD is attached to a linear PEG
spacer, which is conjugated to
the GG residue. The length n of
the PEG spacer depends on the
molecular weight of the linear
PEG molecule: 500 Da; 1,000
Da; and 2,000 Da correspond to
approximately 11, 23, and 45
ethylene glycol monomers
2974 J Mol Model (2011) 17:2973–2987philicity—factors that may influence how nanoparticles
overcome biological barriers [14–18]. It was hypothesized
that the density of nonpeptide RGD (4, 8, 12, and 16
ligands) and molecular weight (MW) of PEG spacer (500
Da; 1,000 Da; and 2,000 Da) concomitantly affects the
shape, flexibility, and surface hydrophilicity of a PGG-
PTX-PEG-npRGD molecule. (Figure 2 shows the pattern-
ing schemes for the PGG-PTX-PEG-npRGD molecules.)
Theoretical insight from the modeling results may be
useful to suggest better molecular designs of PGG-
PTX-PEG-npRGD, ultimately expediting its preclinical
development.
Prior to running MD simulations, a key challenge was to
determine the initial configuration of PGG-PTX-PEG-
npRGD [19]. The combination of flexible polymeric
components (PGG and PEG) and rigid components (PTX
Fig. 2 Abstract representations of the spatial positioning patterns of
paclitaxel (PTX) and (PEG)n-nonpeptide RGD molecules on the PGG
backbone. Patterning schemes apply to all PEG 500, PEG 1000, and
PEG 2000 systems. Each PGG-PTX molecule is composed of 130
poly-γ-glutamyl-glutamate monomers, 26 paclitaxel molecules, and 4,
8, 12, or 16 (PEG)n-nonpeptide RGD molecules. Paclitaxel and
(PEG)n-nonpeptide RGD molecules are attached covalently to the
PGG backbone in a random fashion. Numbers between residues
denote the number of repeating GG residues that are not amino- or
carboxyl-termini GG residues. The amino- and carboxyl-termini GG
residues are represented by black dots at the ends of each line
J Mol Model (2011) 17:2973–2987 2975and npRGD) make PGG-PTX-PEG-npRGD a semiflexible
molecule. Currently, there is no crystallized conformation
representing its experimental form available from the
Protein Data Bank. Therefore, circular dichroism (CD)
spectroscopy was used to determine the presence of chiral
forms of PGG-PTX-PEG-npRGD in aqueous form and
obtain a general idea of its initial structure, which was then
used to construct all-atom (AA) models.
In previous work on protein simulations, once the initial
configuration has been determined, MD simulations were run
to equilibrium, at which point a specific structure is attained
[20, 21]. At this point, the potential energy level of a system
became constant with respect to time. The approach must be
different in the present case. Given the semiflexible nature of
the PGG-PTX-PEG-npRGD, the molecule most likely exists
as a population of related structures, rather than one specific
structure. Therefore, the goal is not to attain a static PGG-
PTX-PEG-npRGD conformation through MD simulations.
Rather, MD simulations are run until minimal structural
fluctuations at the molecular level, or a statistical equilibrium
[22], is reached, at which point a PGG-PTX-PEG-npRGD
molecule is characterized as an ensemble of statistically
similar structures.
Given the relatively large sizes of each PGG-PTX-PEG-
npRGD molecule (∼90–130 kDa), running MD simulations
on AA models in explicit solvent was judged to require an
extraordinary amountofCPUtimeandexpense.Therefore,to
minimize computational costs and allow access longer time
scales, AA models were converted to coarse-grained (CG)
models using the mapping scheme in the MARrink’s Toolkit
INItiative (MARTINI) force field [23]. CG parameterization
of the models was done by using the Boltzmann inversion to
determine the equilibrium bonded distances and angles from
100 ns AA MD simulations in implicit solvent.
Experimental and computational methods
Experimental
Sample preparation
A lyophilized sample of PGG-PTX-PEG220-npRGD16 was
provided by Nitto Denko Technical Corporation (Ocean-
side, CA, USA). The sample was weighed and then diluted
to 1mg/ml in 1X HyClone modified DPBS buffer (Cat. No.
SH30028.03, ThermoScientific, Fremont, CA). The sample
was then sonicated in a 37°C water bath for 15 min and
allowed to settle at room temperature (25°C) for 10 min.
Finally, the sample was filtered using a 0.2 μm filter paper
(Part No. 431215, Corning Life Sciences, San Francisco,
CA, USA) and a 20G 1½ Precision Glide needle (Becton
Dickinson, Franklin Lakes, NJ, USA).
Circular dichroism spectroscopy
CD spectroscopy measurements of the PGG-PTX-
PEG220-npRGD16 sample were carried out using an AVIV
Model 202 spectrophotometer (AVIV Biomedical, Lake-
wood, NJ, USA). CD spectra of pure 1X DPBS buffer and
FD protein in 50% TFE/50% double distilled H2O/0.1%
TFA were also taken as the negative and positive controls,
respectively. All measurements were taken at 37°C. The
far-UV CD spectra were recorded from 190 to 260 nm
using a 1-cm rectangular quartz cuvette, and the CD spectra
were collected at every 0.5 nm with 5 sec at each point. For
each sample except pure 1X DPBS, the concentration was
adjusted and diluted so that the dynode voltage
corresponding to the ellipticity signal remained below
500 V throughout the entire spectra collection period. (It
has been suggested in Greenfield et al. [24] that the signal-
to-noise ratio diminishes greatly once the dynode voltage
exceeds 500 V.) The optimum concentrations of each
sample leading to the optimal elliptical signal and lowest
signal-to-noise ratio were determined to be: 1 mg/ml of
PGG-PTX-PEG220-npRGD16 in 1X DPBS and 0.25 mg/ml
of FD protein in 50% TFE/50% ddH2O/0.1% TFA.
Computational methods
All-atom modeling
Model construction The initial structures and input files for
the following residues were constructed in the xleap
module of AMBER 9.0: GG, GGCOO–,G G NH3+, GG-
PTX, GG-PEG500-npRGD, GG-PEG1000-npRGD, and
GG-PEG2000-npRGD. The initial structure for paclitaxel
(PDB ID: 1JFF) was provided by the Protein Data Bank
[25]. The Gaussian (g03) program’s geometry optimization
and restrained electrostatic potential fitting (RESP) were
used to generate the atom-centered point charges for all
residues [26, 27]. For the protonated molecules, hydrogen
atoms were added to the carboxyl groups to achieve
their ionized states. To obtain the electrostatic potential
for these residues, the AM1 geometry scheme and the
HF/6-31G* and HF/6-31G** pop=mk iop(6/33=2) ab
initio level calculations were performed using the
Gaussian program. Finally, to derive the equivalent
partial atomic charges, RESP fitting was applied on
the electrostatic potentials.
Energy minimization and MD simulation These steps were
carried out using the AMBER 9.0 sander module. Each
molecule was solvated and minimized in implicit solvent
using the modified Generalized-Born model of IGB=2 and
the linear combinations of pairwise overlaps (LPCO) model
[28, 29]; 250 steps of steepest descent followed by 1,750
steps of conjugate gradient were carried out. The ionic
2976 J Mol Model (2011) 17:2973–2987strength of the implicit solvent was set to 140 mM to mimic
the salt concentration of blood plasma. No periodic
boundary conditions were applied. A non-bonded electro-
static cutoff of 16.0 Å was used. Trajectory snapshots were
saved every 100 steps for further reprocessing.
MD simulations were also carried out using the sander
module applying the modified version (ff99SB) of the
Cornell et al. parm99 and GAFF force fields in the NVT
ensemble (in which the number of atoms N, volume V, and
temperature T were fixed) at 310K in implicit solvent
without periodic boundary conditions [30–32]. Constant
temperature scaling was also applied with a time constant
of 0.5 ps. Langevin dynamics was used with a collision
frequency of 2.0 ps
−1. Newton’s equations of motions were
integrated with a time step of 2 fs. All bonds involving
hydrogen atoms were constrained using the SHAKE
algorithm [33]. The rotational and translational degrees of
freedom about the center of mass were eliminated.
Trajectory snapshots were saved every 100 steps for later
reprocessing. Each cycle of the MD simulation was run for
0.1 ns; this step was repeated until a statistical equilibrium
was reached at 100 ns.
Coarse-grained modeling
CG mapping The MARTINI force field was selected for the
CG parameterization for its successful application to proteins
by experimental validation of their structural and
thermodynamic properties as well as the amino acid-based
nature of the glutamyl-glutamate backbone [23, 34]. The
MARTINI force field dictates that a group of roughly four–
five atoms are represented as an interaction center, or bead.
The only exception applies to aromatic groups, in which a
mapping scheme of two heavy atoms-to-one-bead was
applied in order to maintain geometric symmetry, namely,
the benzene entities in paclitaxel and nonpeptide RGD. These
beads interact through a set of short-range Lennard-Jones
potentials to reproduce characteristic properties resulting from
AA simulations. Charged groups interact via a Coulombic
energy function, and bonded potentials are used to describe
the chemical connectivity of the beads. CG mapping of the
GG, GGCOO–,G G NH3+, and GG-PTX residues was previous-
ly done in Peng et al. [22]. CG mapping of the GG-PEG500-
npRGD residue is shown in Fig. 3, and CG mapping of the
GG-PEG1000-npRGD and GG-PEG2000-npRGD residues
are provided in Fig. S2. Also, each Na+ion is represented as
a single Q type bead, and four AA water molecules are
mapped to a single P4 type bead (W).
Theory
The dynamics of the beads are described by Newton’s
equations of motion. The effective bonded and nonbonded
interactions are described by a potential of the form,
adapted from Marrink et al. [34]:
V ¼
X
m
Vm
bond þ Vm
angle þ Vm
dihedral
hi
þ Vm
nonbonded ð2Þ
where the index m represents a bead from a PGG-PTX-PEG-
npRGD molecule, a sodium (Na+) ion, or a water (W) bead.
Vbond represents the forces between two successively bonded
beads, Vbond accounts for the forces used to sustain angles
between three successively bonded beads, and Vdihedral corre-
sponds to the dihedral angle potential for four successively
bonded beads. The Vnonbonded term accounts for the nonbonded
interactions among all of the beads in a system. The bonded
interactions are used to describe the chemical connectivity of
the beads and are characterized as one of the following
(the indices i and j represent two consecutive beads):
Vm
bond ¼
X
ij
1
2km
ij rm
ij   rm
0;ij
   2
ð3Þ
where rm
ij is the distance between two consecutive beads i and j,
rm
0;ij is the equilibrium bond length, and km
ij is the distance force
constant. The potential for bond angles is:
Vm
angle ¼
X
ijk
1
2km
ijk cos qm
ijk
  
  cos qm
0;ijk
   hi 2
ð4Þ
where qm
ijk is the angle between beads i, j,a n dk, qm
0;ijk is the
equilibrium angle, and km
ijk is the angle force constant.
The dihedral potential, Vdihedral, applies only to backbone
protein residues. Since the general structure of PGG-PTX-
PEG-npRGD adapts a random coil, Vdihedral was set to 0 for
all combinations of four successively connected beads:
Vm
dihedral ¼
X
ijkl
km
ijkl 1 þ cos n#m
ijkl   dm
ijkl
   hi
ð5Þ
where n is an integer that represents multiplicity, dm
ijkl is the
phase shift,#m
ijkl is the angle between the plane formed by the
first three beads i, j,a n dk and the plane formed by the last
three beads j, k,a n dl,a n dkm
ijklis the dihedral force constant.
Nonbonded interactions between two beads are described
by a van der Waals (vdW) potential, characterized by a
Lennard-Jones 12-6 potential energy function and a Coulom-
bic potential for charged beads. The following summation is
performed over all pairs of nonbonded beads m and n
separated by a distance of rmn:
Vnonbonded ¼
X
m;n
4"mn
smn
rmn
   12
 
smn
rmn
   6 "#
þ
X
m;n
qmqn
4p"0"rmn
ð6Þ
where constants σmn and εmn are the vdW parameters for the
bead interaction, σmn refers to the closest distance of
J Mol Model (2011) 17:2973–2987 2977approach between two beads m and n,a n dεmn denotes the
strength of the interactions between beads m and n.T h e
charges qm and qn of the mth and nth beads, respectively, and
the vacuum dielectric permittivity ε0 are included. A relative
dielectric constant of ε=15 is assumed for all electrostatic
interactions.
CG parameterization
The bonded distances and angles for the PGG-PTX-PEG-
npRGD molecules were determined as follows: (1) MD
simulations of the 12 AA PGG-PTX-PEG-npRGD models
were run to 100 ns; (2) the bonded distances and values for
the assigned beads were extracted from the AA MD
simulations using the AMBER 9.0 ptraj module; and (3)
the Boltzmann inversion was used to extract the equilibri-
um bonded distances and angles [35]. These values were
averaged for each set of four PGG-PTX-PEG-npRGD
molecules with the same PEG MW. (For example, the
bonded distances and angles for the four PEG1000
molecules were averaged together; the resulting values
were used for the parameterizing the PGG-PTX-PEG1000-
npRGD4, PGG-PTX-PEG1000-npRGD8, PGG-PTX-
PEG1000-npRGD12, and PGG-PTX-PEG1000-npRGD16
molecules.) CG topologies for the GG, GGCOO–,G G NH3+,
and GG-PTX residues were taken from Peng et al. and
shown in Table S1 [22]; CG topologies for the GG-
PEG500-npRGD residue are provided in Table S2; and
CG topologies of the GG-PEG1000-npRGD and GG-
PEG2000-npRGD residues are provided in Table S3.
MD simulation
CG models of the 12 PGG-PTX-PEG-npRGD molecules
were constructed using the atom2cg and itp-generating
scripts provided by the MARTINI tutorials. Each PGG-
PTX-PEG-npRGD molecule was solvated in explicit solvent
comprising of W beads. Due to the negative charges
imparted by the glutamyl-glutamate residues, 234 Na+ions
were added in place of water molecules to neutralize the
system. The simulations were carried out under NPT (the
number of particles N, pressure P, and temperature T are
fixed) conditions at a constant temperature of 310 K with a
coupling constant of τT=0.1 ps and a constant pressure of 1
bar with a relaxation time of τP=0.5 ps. The cutoff length
used for the nonbonded interactions was rcut=1.2 nm.
Lennard-Jones and Coulombic forces were considered for
rcut<0.9 nm and rcut<1.2 nm, respectively. Coulombic
Fig. 3 Coarse-grained representation of a GG-PEG500-npRGD residue. A GG-PEG500-npRGD molecule was reduced from 75 heavy atoms to
21 CG beads. (CG representations for the GG-PEG1000-npRGD and GG-PEG2000-npRGD residues are shown in Figs. S1 and S2, respectively)
2978 J Mol Model (2011) 17:2973–2987forces were computed every time step for 1.0 nm and once
every 10 time steps for 0.9 nm<rcut<1.2 nm. The time step
in the leap-frog integration scheme was 5 fs. The energies,
coordinates and velocities were written every 0.5 ps. MD
simulations were run for 1 μs. The timescale was scaled up
by a factor of four because CG dynamics are faster than all-
atom dynamics, due to the smoothness of the CG inter-
actions. This factor of four is based on the speedup in the
diffusional dynamics of CG water as compared to AAwater.
Therefore, the 1 μs simulation timescale was scaled up by a
factor of four, resulting in an effective time of 4 μs
[23, 34, 36].
Root-mean-square deviation clustering
Root-mean-square deviation (RMSD) clustering—aq u a n t i t a -
tivemethodusedtoanalyzeproteinstructures[37]—was used
to determine the PGG-PTX-PEG-npRGD conformations. All
molecular conformations accessed throughout an MD
simulation were categorized into clusters based on structural
similarity. For each cluster, a structure from the MD
trajectory closest to the conformational average of all
structures in the MD trajectory was regarded as the
representative conformation. Using the g_cluster module of
the GROMACS 4.0.3 package, the RMSD cutoff length was
optimized manually so as to meet the following criteria: (1)
there were approximately 40 clusters total, (2) very few
clusters contained just one representative conformation, and
(3) 90% of the MD trajectory was in clusters fewer than
those with one representative conformation. Table 1 provides
the optimized RMSD cutoff distances for all 12 PGG-PTX-
PEG-npRGD molecules. (Sample optimization of the RMSD
cutoff length vs. number of clusters generated for the GG-
PTX-PEG1000-npRGD12 molecule is shown in Fig. S2.)
After optimization of the RMSD cutoff lengths, the signifi-
cance ofevery representativeconformationwas assessedsuch
thatits corresponding framesoccupyatleast 10% ofthe entire
4 μs trajectory. Once the representative conformations were
judgedtobesufficientlysignificant,eachwasevaluatedforits
uniqueness as follows: if the RMSD between the significant
representative conformations of each significant cluster were
greater than twice the RMSD cutoff length, then those
significant representative conformation(s) was/were regarded
as unique. (For the PGG-PTX-PEG-npRGD molecules with
only one significant representative conformation, that confor-
mation was automatically deemed unique.) To verify the
uniqueness among clusters, the RMSD Calculator tool in
Visual Molecular Dynamics 1.8.6 was used [38].
Table 1 Summary of data from root-mean-square deviation (RMSD)
clustering method. The RMSD cutoff lengths optimized for each
PGG-PTX-PEG-npRGD molecule and the corresponding number of
clusters are listed, as well as the unique and significant central
members and the corresponding RMSD between each central member
System RMSD cutoff
(nm)
Number of
clusters
Representative
conformations
RMSD between representative
conformations
PEG500
4 nonpeptide RGD 0.57 37 A B 17.7
8 nonpeptide RGD 0.59 38 A B 7.2
12 nonpeptide RGD 0.56 37 ––
16 nonpeptide RGD 0.53 40 A B 6.6
PEG1000
4 nonpeptide RGD 0.59 37 A B 8.0
8 nonpeptide RGD 0.61 38 A B 6.2
8 nonpeptide RGD 0.61 38 A C 4.9
8 nonpeptide RGD 0.61 38 B C 4.1
12 nonpeptide RGD 0.52 39 A B 9.6
12 nonpeptide RGD 0.52 39 A C 7.3
12 nonpeptide RGD 0.52 39 B C 4.3
16 nonpeptide RGD 0.53 40 ––
PEG2000
4 nonpeptide RGD 4.6 36 ––
8 nonpeptide RGD 0.60 38 ––
12 nonpeptide RGD 0.93 37 ––
16 nonpeptide RGD 0.59 38 ––
J Mol Model (2011) 17:2973–2987 2979Density analysis
Typically in MD simulations, the radial distribution
function, g(r), is used to characterize the structure of the
biomolecules. The gAB(r) between species A and B is
defined as follows [39]:
gABðrÞ¼
rABðrÞ
rB;local
ð7Þ
where ρAB(r) is the density of species B at a distance r from
species A and ρB,local is the local density of species B at
maximum distance rmax from species A. For this study,
species B refers to a PGG-PTX-PEG-npRGD molecule and
species A its center-of-mass (COM). It is important to
emphasizethattheCOMdoesnotnecessarilycorrespondtothe
geometric center, particularly for irregularly shaped molecules,
and the COM is always towards the more massive end.
Since the local densities of the PGG-PTX-PEG-npRGD
molecules are different, their gAB(r) values would not
properly describe how the structure of PGG-PTX-PEG-
npRGD is affected by PEG MW and npRGD density.
Therefore, the density of PGG-PTX-PEG-npRGD from its
COM, ρAB(r), was used to describe structure. The local
density of each PGG-PTX-PEG-npRGD molecule, ρB,local,
was determined from its molecular mass and simulation box
size (see Table 2). The g_rdf module of GROMACS 4.0.3
was then used to extract the gAB(r) values of each PGG-
PTX-PEG-npRGD molecule throughout the 4 μst r a j e c t o r y .
Using the definition of gAB(r), the density of PGG-PTX-
PEG-npRGD from its spatial center was determined by
multiplying gAB(r)a n dρB,local: ρAB(r)=gAB(r)×ρB,local.
Solvent-accessible surface area analysis
The solvent-accessible surface area (SASA) indicates the
area of a particular species that is exposed to the solvent.
The SASA of the PGG-PTX-PEG-npRGD molecules was
analyzed in VMD 1.8.6 using a solvent probe radius of
2.4 nm. For each PGG-PTX-PEG-npRGD molecule, the
SASA of the entire molecule was calculated, along with the
SASA of PGG, PEG, PTX, and npRGD entities of each
PGG-PTX-PEG-npRGD molecule. The contribution of each
entity was then determined by taking the fraction of the
SASA for a particular entity with respect to the SASA of the
whole PGG-PTX-PEG-npRGD molecule, or the percentage
(%) SASA. Table 3 shows the % SASA for the PGG, PEG,
PTX, and npRGD entities for all PGG-PTX-PEG-npRGD
molecules. The hydrophilic SASA (% SASAphil)w a s
determined from the sum of the % SASAPGG and %
SASAPEG residues.
Results and discussion
Circular dichroism spectroscopy
Circular dichroism spectroscopy was used to determine the
secondary structure of a PGG-PTX-PEG220-npRGD16
molecule. This method of determining the initial structure
was originally applied to PGG-PTX in Peng et al. [22].
Although PGG-PTX-PEG220-npRGD16 was not one of the
PGG-PTX-PEG-npRGD molecules pursued in this study,
its chemical structure is similar enough to provide an
accurate representation of the PGG-PTX-PEG-npRGD
molecules being studied.
Figure 4 shows the CD spectra of 1mg/ml PGG-PTX-
PEG220-npRGD16 dissolved in 1X DPBS. The curve is
most representative of a random coil at physiological
temperature (37°C). The negative control of 1X DPBS at
37°C indicates that there is no signal interference that may
have influenced the conditions while the CD spectrum of
PGG-PTX-PEG220-npRGD16 was being taken. For the
System Mass
(kDa)
Mass
(× 10
−19 g)
Simulation box
volume (× 10
3 nm
3)
Local density, ρB,local
(× 10
−3 g/ml)
PGG-PTX-PEG500-npRGD4 58.6 0.97 5.60 17.4
PGG-PTX-PEG500-npRGD8 61.9 1.03 5.07 20.3
PGG-PTX-PEG500-npRGD12 65.1 1.08 5.72 18.9
PGG-PTX-PEG500-npRGD16 68.5 1.14 5.54 20.5
PGG-PTX-PEG1000-npRGD4 60.6 1.01 6.33 15.9
PGG-PTX-PEG1000-npRGD8 65.8 1.09 6.79 16.1
PGG-PTX-PEG1000-npRGD12 71.0 1.18 9.35 12.6
PGG-PTX-PEG1000-npRGD16 76.2 1.27 9.26 13.7
PGG-PTX-PEG2000-npRGD4 64.8 1.08 13.4 8.03
PGG-PTX-PEG2000-npRGD8 74.2 1.23 16.3 7.58
PGG-PTX-PEG2000-npRGD12 83.7 1.39 24.1 5.77
PGG-PTX-PEG2000-npRGD16 93.1 1.55 24.4 6.34
Table 2 Determination of local
densities of PGG-PTX-PEG-
npRGD molecules. The local
density, ρB,local, of each PGG-
PTX-PEG-npRGD molecule
was determined by dividing the
mass of each molecule by the
simulation box volume using the
following unit conversions:
6.022 × 10
23 Da = 1 gram and 1
nm
3 = 1.0 × 10
−21 ml
2980 J Mol Model (2011) 17:2973–2987positive control, the shape of the alpha-helical FD protein, a
bZIP transcription factor in a floral pathway [40], in 50%
TFE/50% ddH2O/0.1% TFA buffer does indeed correspond
to an alpha-helix, as compared with the CD spectrum of the
alpha-helical poly(γ-tyrosine) [41]. The lowest part of the
curve is ∼215 nm and the highest point of the curve is
∼200 nm, collectively indicating that the FD protein is
alpha-helical. Since PGG-PTX-PEG220-npRGD16 exists as
a random coil, this data suggest that the PGG-PTX-PEG-
npRGD molecules being modeled most likely exist as
random coils. Therefore, their existence as random coils
imposes no stipulations on the construction of AA models
of PGG-PTX-PEG-npRGD. Also, the CD spectroscopy
results further support the theory that the conformation of
PGG-PTX-PEG-npRGD is not limited to a specific struc-
ture, and structural analysis must account for multiple
conformations of PGG-PTX-PEG-npRGD.
RMSD values
Figure 5 shows the RMSD time evolutions for all
PGG-PTX-PEG-npRGD molecules. Most time evolutions
i n c r e a s e du pt o∼6-7 nm and reached a statistical
equilibrium by 4 μs. Given the relatively large sizes of
Fig. 4 Circular dichroism spectra of samples. The spectra for 16
nonpeptide RGD-targeted PGG-PTX (red), PGG-PTX (blue), FD
protein (green), and pure 1X DPBS (black) are shown
System % SASAPGG % SASAPEG % SASAphil* % SASAPTX % SASAnpRGD
PEG 500
4 nonpeptide RGD
A 78.5 1.1 79.6* 18.2 2.2
B 69.5 1.9 71.4* 25.7 2.9
8 nonpeptide RGD
A 73.1 1.6 74.7* 21.5 3.9
B 73.3 1.5 74.8* 20.4 4.9
12 nonpeptide RGD 68.2 2.8 70.0* 19.0 8.2
16 nonpeptide RGD
A 66.9 3.7 70.6* 18.7 10.6
B 58.1 6.2 64.3* 23.8 11.8
PEG1000
4 nonpeptide RGD
A 74.2 0.3 74.5* 24.2 1.2
B 74.9 1.1 76.0* 22.3 1.8
8 nonpeptide RGD
A 78.3 2.0 80.3* 16.4 3.4
B 64.7 5.8 70.5* 25.2 4.3
C 71.7 2.4 74.1* 22.8 3.1
12 nonpeptide RGD
A 78.7 0.5 79.2* 15.0 5.8
B 73.2 0.4 73.6* 18.7 7.7
C 73.9 0.4 74.3* 18.8 6.9
16 nonpeptide RGD 74.1 0.6 74.7* 16.0 9.2
PEG2000
4 nonpeptide RGD 78.9 1.8 80.7* 17.8 1.5
8 nonpeptide RGD 72.6 6.5 79.1* 17.0 3.8
12 nonpeptide RGD 68.3 8.4 76.7* 16.9 6.4
16 nonpeptide RGD 66.0 12.5 78.5* 12.3 9.2
Table 3 Percentage solvent-
accessible surface area(SASA) of
PGG-PTX-PEG-npRGD
molecules. Lists the percentage
SASAvalues for the PGG, PEG,
PTX, and npRGD entities with
respecttotheentireSASAofeach
PGG-PTX-PEG-npRGD
molecule
*The % SASAphil is the sum of
the%SASAPGG and % SASAPEG
J Mol Model (2011) 17:2973–2987 2981these systems, these values are reasonable. The RMSD
values for the PEG2000 molecules are slightly higher than
those of the PEG500 and PEG1000 molecules (by ∼1 nm),
whereas the RMSD values for the PEG500 and PEG1000
molecules are comparable. This 1 nm difference is in
accordance with the size of the molecular systems, as the
PEG2000 molecules are the largest. In addition, the time it
takes for PGG-PTX-PEG-npRGD molecules to attain
statistical equilibrium depends on the PEG MW. The
PEG1000moleculestakethelongesttimetoreachequilibrium,
as some molecules do not reached a plateau until 3 μs.
Conversely, the PEG2000 molecules take the least time to
reach equilibrium; by 1 μs, all molecules have attained a
statistical equilibrium. The time it takes for the PEG500
moleculestoleveloffis∼2μs,whichisintermediatecompared
to the time it takes for the PEG1000 and PEG2000 molecules
toreachequilibrium.This behavior suggests thatthePEG1000
molecules fluctuate the most, accessing a wide range of
molecular conformations throughout the 4 μsM Dt r a j e c t o r y .
Size of a PGG-PTX-PEG-npRGD molecule
Figure 6 shows the radius of gyration (Rgyr) trajectories for
all PGG-PTX-PEG-npRGD molecules over the 4 μs time
scale. For all molecules, the Rgyr values begin at ∼7–8n m
and decrease to ∼3 nm, nearly half their original size. The
PEG2000 and PEG1000 systems take the shortest and
longest to reach their final Rgyr values, respectively. These
values correspond to the RMSD values: the PEG2000 and
PEG1000 systems also take the shortest and longest to
reach their final RMSD values, respectively. Furthermore,
as shown in Fig. 7, the Rgyr of each PGG-PTX-PEG-
npRGD representative conformation is approximately 2-
4 nm. Figure 8 further supports the notion that neither the
PEG MW nor the npRGD density significantly influences
the size of a PGG-PTX-PEG-npRGD molecule.
Structure of a PGG-PTX-PEG-npRGD molecule
Figure 9 shows that each PGG-PTX-PEG-npRGD molecule
is most densely packed at its COM. Most PGG-PTX-PEG-
npRGD molecules exhibit a peak density of ∼1 g/ml just
outside its center-of-mass at r∼1 nm, 1.5 nm, and 2 nm for
the PEG500, PEG1000, and PEG2000 molecules. This
increase in distance of peak density is correlated with
increasing PEG MW. Figure 8 shows how the density of
each residue type (PGG, PTX, PEG, and npRGD) varies
from the COM of a PGG-PTX-PEG-npRGD molecule. The
PEG MW impacts how the density of each residue changes
with distance from COM. For instance, PTX and npRGD
residues exhibit peak densities at greater distances as PEG
MW increases, suggesting that higher PEG MW causes
PTX and npRGD residues to approach closer to the surface
of the PGG-PTX-PEG-npRGD. The peak densities of PTX
Fig. 5 RMSD time evolutions of PGG-PTX-PEG-npRGD molecules.
Data for molecules with 4 (PEG)n-nonpeptide RGD molecules (blue),
8 (PEG)n-nonpeptide RGD molecules (green), 12 (PEG)n-nonpeptide
RGD molecules (red), and 16 (PEG)n-nonpeptide RGD molecules
(black) are shown
Fig. 6 Radius of gyration trajectories of PGG-PTX-PEG-npRGD
PTX molecules. Data for molecules with 4 (PEG)n-nonpeptide RGD
molecules (blue), 8 (PEG)n-nonpeptide RGD molecules (green), 12
(PEG)n-nonpeptide RGD molecules (red), and 16 (PEG)n-nonpeptide
RGD (black) molecules are shown
2982 J Mol Model (2011) 17:2973–2987and npRGD in Fig. 8 agree with the peak densities of PGG-
PTX-PEG-npRGD in Fig. 9, suggesting that the presence of
PTX and npRGD residues is mostly responsible for this
spatial shift in the peak density of the overall PGG-PTX-
PEG-npRGD molecule. On the contrary, for PEG, the
distance of peak density tends to decrease as the PEG MW
increases, which suggests that increasing the PEG spacer
length causes PEG to shift away from the external surface
and move internally towards the COM of a PGG-PTX-
PEG-npRGD molecule. In general, the difference in peak
densities of PEG and peak densities of PTX and npRGD
becomes more pronounced as the PEG MW increases,
which signifies that the PGG-PTX-PEG-npRGD molecule
tends to become more spatially divided (by residue type) at
higher PEG MW. Finally,takingtheRgyr values into account,
these results suggest that while the PEG MW does not affect
the size of a PGG-PTX-PEG-npRGD molecule, the PEG
MW does impact structure. Figure 8 also suggests that the
npRGD density also does not significantly affect the
structure of the PGG-PTX-PEG-npRGD molecule.
Implications of shape of a PGG-PTX-PEG-npRGD molecule
Discher and colleagues have demonstrated that filamentous
particles retains a longer circulation half-life in the
bloodstream, thus decreasing levels of clearance via the
reticoendothelial system (RES) and improving the chances
of the nanoparticle to reach the target tumor [16]. Also,
nonspherical nanoparticles have been shown to adhere
more firmly to walls of tumor endothelia [17]. Figure 7
shows the representative conformations of all PGG-PTX-
PEG-npRGD molecules. The geometry of each molecule is
characterized as a filament (wormlike and threadlike) or
globule (round). In general, most molecules are globules,
which is most likely attributed to the hydrophobic driving
force among PTX molecules that are uniformly distributed
along the PGG backbone. The uniform distribution of PTX
causes the entire PGG-PTX-PEG-npRGD to self-assemble
into a globule in which PTX molecules are located in the
core, where it is the furthest from the solvent and
surrounded by hydrophilic PGG. Other molecules, such as
Fig. 7 Representative conformations of PGG-PTX-PEG-npRGD
molecules. Each structure shows GG (grey), PTX (yellow), PEG
(blue), and npRGD (red) residues. Explicit W beads and Na
+ions are
not shown. Representing an actual frame in the trajectory, the central
member embodies the configuration that is the most similar to the
average of all configurations in that cluster. The percentage indicates
the population of frames, or % trajectory occupancy, corresponding to
that particular cluster for the full 4 μs MD trajectory. Radius of
gyration values for each PGG-PTX-PEG-npRGD molecule is also
shown below the % trajectory occupancy
J Mol Model (2011) 17:2973–2987 2983PGG-PTX-PEG1000-npRGD4 and PGG-PTX-PEG1000-
npRGD12, exhibit both filamentous and globular behavior.
The shape of the PGG-PTX-PEG-npRGD molecule is not
significantly affected by the npRGD density but by the
PEG MW. The PEG1000 molecules exhibit the most
filamentous behavior, as each one of its four molecules is
characterized by a filamentous conformation. The higher
prominence of filaments in the PEG500 and PEG1000
molecules is possibly a result of the sterical interactions
among the rigid, conformationally constrained nonpeptide
RGD residues that hinder the formation of a more compact
globule. For the PEG2000 molecules, however, the prom-
inence of the globular shapes (∼90%) suggests that 2,000
Da is the PEG MW most likely to prevent sterical
interactions among nonpeptide RGD residues, thus allow-
ing the PGG-PTX-PEG-npRGD molecules to form a
globule. Overall, the results suggest that PGG-PTX-PEG-
npRGD molecules with PEG500 and PEG1000 spacers are
Fig. 8 Density of residues from COM of a PGG-PTX-PEG-npRGD molecules. Data for poly(glutamyl-glutamate) (green), paclitaxel (black),
poly(ethylene) glycol (purple), and nonpeptide RGD (orange) are shown
Fig. 9 Density of PGG-PTX-
PEG-npRGD molecules from
COM. Data for molecules with 4
(PEG)n-nonpeptide RGD mole-
cules (blue), 8 (PEG)n-nonpep-
tide RGD molecules (green), 12
(PEG)n-nonpeptide RGD mole-
cules (red), and 16 (PEG)n-non-
peptide RGD molecules (black)
are shown
2984 J Mol Model (2011) 17:2973–2987more efficacious than the PGG-PTX-PEG-npRGD molecules
with PEG2000 spacers. While the molecular weight of the
PEGspacerinfluencestheshapeofaPGG-PTX-PEG-npRGD
molecule, the npRGD density has only minimal impact.
Implications of flexibility of a PGG-PTX-PEG-npRGD
molecule
Takeoka has speculated that higher molecular flexibility of
nanoparticles promotes more surface interactions to tumor
cells [18]. The flexibility of each PGG-PTX-PEG-npRGD
molecule was assessed by the number of representative
conformations of each molecule and, for those systems with
multiple representative conformations, the similarity among
representative conformations. A higher number of repre-
sentative conformations indicates a stronger tendency for
that molecule to fluctuate and change shape. The PEG1000
molecules have the most representative conformations; the
PGG-PTX-PEG1000-npRGD8 and PGG-PTX-PEG1000-
npRGD12 molecules are characterized by three representa-
tive conformations, although with low significance (∼10–
20%). On the contrary, each PEG2000 molecule has only
one unique shape with very high significance (∼90%).
Moreover, the degree of similarity among the representative
conformations is also an indicator of flexibility: a PGG-
PTX-PEG-npRGD molecule with two globular representa-
tive conformations is less flexible than a molecule
characterized by globular and filamentous conformations.
For instance, PGG-PTX-PEG500-npRGD4 and PGG-PTX-
PEG1000-npRGD4 each has two representative conforma-
tions, but a larger structural difference exists between the
globular and filamentous shapes of the PGG-PTX-PEG500-
npRGD4 molecule, as compared to the two filamentous
conformations of the PGG-PTX-PEG1000-npRGD4 mole-
cule. In all, these observations show that the PEG2000
molecules are the least flexible, whereas the PEG500 and
PEG1000 molecules are more flexible and would therefore
bind more effectively to tumor cells. Finally, the npRGD
ligand density does not have a significant effect on the
flexibility of a PGG-PTX-PEG-npRGD molecule.
Implications of surface hydrophilicity of a PGG-PTX-PEG-
npRGD molecule
Nanoparticles with higher degrees of surface hydrophilicity
have been shown to possess longer circulation half-lives in
the bloodstream, suggesting a higher preference for
accumulating in leaky vasculature of tumors [14]. The
degree of surface hydrophilicity of each PGG-PTX-PEG-
npRGD molecule was assessed by the % SASA of the
hydrophilic entities: PGG and PEG (see Table 3). These %
SASA values are related to the density plots in Fig. 9.I n
general, the high % SASAPGG values can be attributed to
the high density values at r∼3 nm, at the external surface of
the PGG-PTX-PEG-npRGD molecule. Likewise, the %
SASAPEG values are the lowest, which is a result of the
high concentration of PEG near the center-of-mass and not
the surface. Figure 8 also shows that the densities of PTX
and npRGD residues are relatively high near the surface of
a PGG-PTX-PEG-npRGD molecule, but their low molec-
ular weight ratio with respect to the entire molecule results
in lower % SASAPTX and % SASAnpRGD values than %
SASAPGG. As expected, the surface hydrophilicity
increases with PEG MW, and an increase in npRGD
density results in higher % SASAnpRGD. A higher npRGD
density also tends to cause a decrease in the % SASAphil.
While nonpeptide RGD is used to promote active targeting
of PGG-PTX to tumor cells, too many nonpeptide RGD
ligands may decrease surface hydrophilicity, which may
unfavorably decrease to the circulation half-life. PGG-
PTX-PEG-npRGD must remain in the bloodstream long
enough to diffuse convectively into leaky tumor vascula-
ture. At the same time, adequate amounts of nonpeptide
RGD ligands must be exposed to the solvent to achieve
effective binding to αVβ3 integrins. Therefore, optimiza-
tion of npRGD density is necessary to attain optimal
efficacy of PGG-PTX-PEG-npRGD. Taking these factors
into consideration, the PGG-PTX-PEG-npRGD molecules
with 8 and 12 npRGD and PEG1000 and PEG2000 MW
are most likely to confer the longest circulation half-lives
and effective targeting to αVβ3 integrins on tumor cells.
Recommendations
This study was founded on the hypothesis that the degree of
PEGylation (500 Da; 1,000 Da; and 2,000 Da) and npRGD
density (4, 8, 12, and 16 nonpeptide RGD per PGG-PTX-
PEG-npRGD molecule) collectively affect the size, structure,
shape, flexibility, and surface hydrophilicity of PGG-PTX-
PEG-npRGD. While the size of a PGG-PTX-PEG-npRGD
molecule is consistent at all PEG MWand npRGD densities,
the molecular density tends to be is higher at the surface at
higher PEG MW. The results also show that the PEG500 and
PEG1000moleculesexhibitedmorefilamentousbehaviorand
higher flexibility, whereas the PEG2000 molecules are
globular and more rigid. An increase in the nonpeptide
RGD ligand density may result in lower surface hydro-
philicity, yet an insufficient number of nonpeptide RGD
ligands may prevent PGG-PTX-PEG-npRGD from achiev-
ing effective targeting to tumor cells. All factors consid-
ered, the ideal PGG-PTX-PEG-npRGD candidate would
possess the following properties: filamentous shape, high
flexibility, and high surface hydrophilicity. Based on the
results, the PGG-PTX-PEG1000-npRGD4 and PGG-PTX-
PEG1000-npRGD8 molecules most satisfy these criteria
and are the most promising candidates.
J Mol Model (2011) 17:2973–2987 2985Conclusions
The roles of shape, flexibility, and surface hydrophilicity in
influencing the delivery of therapeutic nanoparticles to
tumors have attracted increasing attention. These factors
can serve as a basis for the design of anticancer
therapeutics, such as PGG-PTX-PEG-npRGD. While it
may be technically feasible to determine these properties
using experimental methods, the effort required to synthe-
size all candidate compounds and subsequently perform
experimental testing would be very time- and resource-
intensive, especially since the testing is usually conducted
in a trial-and-error manner. Therefore, MD simulations
were used to explore the size, shape, flexibility, and
surface hydrophilicity of candidate PGG-PTX-PEG-
npRGD compounds in a more efficient and controlled
manner. The theoretical results can be used to further
guide experiments, potentially shortening the preclinical
development of PGG-PTX-PEG-npRGD. This study also
introduces a new structural analysis method of character-
izing semiflexible molecules without a specific, crystal-
lized conformation.
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